We initiate coverage of ANGLE, a revenue generating specialist diagnostics company focused on advancing, and commercialising, new approaches to liquid (blood) biopsy testing in cancer. ANGLE’s flagship product is the Parsortix system, a unique, cell separation system that captures and harvests circulating tumour cells (CTCs) from blood, allowing in-depth, repeatable downstream analysis of a patient’s cancer. We believe ANGLE’s equity story is now one centred on commercial execution, with top-lin ....
